These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 31553932)
1. Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma. Ding Y; Li S; Ge W; Liu Z; Zhang X; Wang M; Chen T; Chen Y; Zhang Q Eur J Med Chem; 2019 Dec; 183():111706. PubMed ID: 31553932 [TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of parthenolide-SAHA hybrids for intervention of drug-resistant acute myeloid leukemia. Ge W; Liu Z; Sun Y; Wang T; Guo H; Chen X; Li S; Wang M; Chen Y; Ding Y; Zhang Q Bioorg Chem; 2019 Jun; 87():699-713. PubMed ID: 30953889 [TBL] [Abstract][Full Text] [Related]
3. Reversing resistance of multidrug-resistant hepatic carcinoma cells with parthenolide. Liu D; Liu Y; Liu M; Ran L; Li Y Future Oncol; 2013 Apr; 9(4):595-604. PubMed ID: 23560381 [TBL] [Abstract][Full Text] [Related]
4. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells. Ke M; Dong J; Wang Y; Zhang J; Zhang M; Wu Z; Lv Y; Wu R Int J Biochem Cell Biol; 2018 Aug; 101():39-48. PubMed ID: 29800725 [TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells. Zhang L; Liu L; Zheng C; Wang Y; Nie X; Shi D; Chen Y; Wei G; Wang J Eur J Med Chem; 2017 May; 131():81-91. PubMed ID: 28301815 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy. Yue K; Hou X; Jia G; Zhang L; Zhang J; Tan L; Wang X; Zhang Z; Li P; Xu W; Li X; Jiang Y Bioorg Chem; 2021 Nov; 116():105343. PubMed ID: 34544027 [TBL] [Abstract][Full Text] [Related]
7. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. Chen Z; Ma T; Huang C; Zhang L; Lv X; Xu T; Hu T; Li J Cell Signal; 2013 Dec; 25(12):2693-701. PubMed ID: 24018051 [TBL] [Abstract][Full Text] [Related]
8. Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma. Liu Z; Wang Y; Yao Y; Fang Z; Miao QR; Ye M J Proteomics; 2019 Sep; 208():103501. PubMed ID: 31454556 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods. Zhong X; Xiong M; Meng X; Gong R J Exp Clin Cancer Res; 2010 Aug; 29(1):115. PubMed ID: 20727186 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents. Dai M; Yuan X; Kang J; Zhu ZJ; Yue RC; Yuan H; Chen BY; Zhang WD; Liu RH; Sun QY Eur J Med Chem; 2013 Nov; 69():159-66. PubMed ID: 24013415 [TBL] [Abstract][Full Text] [Related]
11. Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. Gu W; Fang FF; Li B; Cheng BB; Ling CQ Asian Pac J Cancer Prev; 2012; 13(9):4807-14. PubMed ID: 23167424 [TBL] [Abstract][Full Text] [Related]
12. Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). Jin J; Huang M; Wei HL; Liu GT World J Gastroenterol; 2002 Dec; 8(6):1029-34. PubMed ID: 12439919 [TBL] [Abstract][Full Text] [Related]
13. TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human hepatocellular carcinoma BEL-7402/5-FU cells. Lu F; Hou YQ; Song Y; Yuan ZJ Anat Rec (Hoboken); 2013 Jan; 296(1):56-63. PubMed ID: 23125179 [TBL] [Abstract][Full Text] [Related]
14. Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells. Li JQ; Wu X; Gan L; Yang XL; Miao ZH Acta Pharmacol Sin; 2017 Dec; 38(12):1642-1654. PubMed ID: 28713155 [TBL] [Abstract][Full Text] [Related]
15. The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging. Li H; Du G; Yang L; Pang L; Zhan Y Anticancer Agents Med Chem; 2020; 20(9):1147-1156. PubMed ID: 32106805 [TBL] [Abstract][Full Text] [Related]
16. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells. Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654 [TBL] [Abstract][Full Text] [Related]
17. Discovery of novel isatin-dehydroepiandrosterone conjugates as potential anticancer agents. Ke S; Shi L; Yang Z Bioorg Med Chem Lett; 2015 Oct; 25(20):4628-31. PubMed ID: 26320625 [TBL] [Abstract][Full Text] [Related]
18. Discovery of penipanoid C-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-one derivatives as potential anticancer agents by inhibiting cell proliferation and inducing apoptosis in hepatocellular carcinoma cells. Wang CJ; Guo X; Zhai RQ; Sun C; Xiao G; Chen J; Wei MY; Shao CL; Gu Y Eur J Med Chem; 2021 Nov; 224():113671. PubMed ID: 34237623 [TBL] [Abstract][Full Text] [Related]
19. Annonaceous acetogenins reverses drug resistance of human hepatocellular carcinoma BEL-7402/5-FU and HepG2/ADM cell lines. Qian JQ; Sun P; Pan ZY; Fang ZZ Int J Clin Exp Pathol; 2015; 8(9):11934-44. PubMed ID: 26617951 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma. Harras MF; Sabour R Bioorg Chem; 2018 Aug; 78():149-157. PubMed ID: 29567429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]